A Comprehensive Approach Toward Novel Serum Biomarkers for Benign Prostatic Hyperplasia: The MPSA Consortium

Journal of Urology

Volumn 179, Issue 4, 2008, Pages 1243-1256

  Mullins, Chris ^a   Lucia, M Scott ^c   Hayward, Simon W ^d   Lee, Jeannette Y ^e   Levitt, Jonathan M ^f   Lin, Victor K ^g   Liu, Brian C S ^h   Chinnaiyan, Arul M ^h,i   Rubin, Mark A ^h,i   Slawin, Kevin ^f   Star, Robert A ^a   Getzenberg, Robert H ^b  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Department of Pathology   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

^g UNIVERSITY OF TEXAS AT DALLAS   (United States)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

ⁱ MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

biological markers; prostatic hyperplasia; urologic diseases

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANDROGEN; BIOLOGICAL MARKER; DUTASTERIDE; FINASTERIDE; PROSTATE SPECIFIC ANTIGEN;

CLINICAL TRIAL; DISEASE MARKER; DRUG RESPONSE; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; HUMAN; LOWER URINARY TRACT SYMPTOM; MICROARRAY ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATECTOMY; REVIEW;

ADULT; AGED; BIOLOGICAL MARKERS; HUMANS; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA;

EID: 40849113211     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2007.11.049     Document Type: Review

References (50)

1. Roehrborn C.G., McConnell J.D., Saltzman B., Bergner D., Gray T., Narayan P., et al. Storage (irritative) and voiding (obstructive) symptoms as predictors of benign prostatic hyperplasia progression and related outcomes. Eur Urol 42 (2002) 1
2. McVary K.T. BPH: epidemiology and comorbidities. Am J Manag Care 12 (2006) S122
3. Wei J.T., Calhoun E., and Jacobsen S.J. Urologic Diseases in America Project: benign prostatic hyperplasia. J Urol 173 (2005) 1256
4. Sarma A.V., Jacobson D.J., McGree M.E., Roberts R.O., Lieber M., and Jacobsen S.J. A population based study of incidence and treatment of benign prostatic hyperplasia among residents of Olmsted County, Minnesota: 1987 to 1997. J Urol 173 (2003) 2048
5. Chapple C.R. Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practising clinician. BJU Int 94 (2004) 738
6. McConnell J.D., Roehrborn C.G., Baustista O.M., Andriole Jr. G.L., Dixon C.M., Kusek J.W., et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349 (2003) 2387
7. Hewitt S.M., Dear J., and Star R.A. Discovery of protein biomarkers for renal diseases. J Am Soc Nephrol 15 (2004) 1677
8. De Gruttola V.G., Clax P., DeMets D.L., Downing G.J., Ellenberg S.S., Friedman L., et al. Considerations in the evaluation of surrogate endpoints in clinical trials: summary of a National Institutes of Health workshop. Control Clin Trials 22 (2001) 485
9. Anim J.T., Udo C., and John B. Characterisation of inflammatory cells in benign prostatic hyperplasia. Acta Histochem 100 (1998) 439
10. Nickel J.C., Downey J., Young I., and Boag S. Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. BJU Int 84 (1999) 976
11. Di Silverio F., Gentile V., DeMatteis A., Mariotti G., Giuseppe V., Luigi P.A., et al. Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. Eur Urol 43 (2003) 164
12. Mahapokai W., van den Ingh T.S., van Mil F., van Garderen E., Schalken J.A., Mol J.A., et al. Immune response in hormonally-induced prostatic hyperplasia in the dog. Vet Immunol Immunopathol 78 (2001) 297
13. Prakash K., Pirozzi G., Elashoff M., Munger W., Waga I., Dhir R., et al. Symptomatic and asymptomatic benign prostatic hyperplasia: molecular differentiation by using microarrays. Proc Natl Acad Sci U S A 99 (2002) 7598
14. Ehrlich J.R., Qin S., and Liu B.C. The 'reverse capture' autoantibody microarray: a native antigen-based platform for autoantibody profiling. Nat Protoc 1 (2006) 452
15. Qin S., Qiu W., Ehrlich J.R., Ferdinand A.S., Richie J.P., O'Leary M.P., et al. Development of a "reverse capture" autoantibody microarray for studies of antigen-autoantibody profiling. Proteomics 6 (2006) 3199
16. DiCunto F., Calautti E., Hsiao J., Ong L., Topley G., Turco E., et al. Citron rho-interacting kinase, a novel tissue-specific ser/thr kinase encompassing the Rho-Rac-binding protein Citron. J Biol Chem 273 (1998) 29706
17. Yamashiro S., Totsukawa G., Yamakita Y., Sasaki Y., Madaule P., Ishizaki T., et al. Citron kinase, a Rho-dependent kinase, induces di-phosphorylation of regulatory light chain of myosin II. Mol Biol Cell 14 (2003) 1745
18. Staack A., Donjacour A.A., Brody J., Cunha G.R., and Carroll P. Mouse urogential development: a practical approach. Differentiation 71 (2003) 402
19. Shah U.S., Arlotti J., Dhir R., Lu S., Pirozzi G., Prakash K., et al. Androgen regulation of JM-27 is associated with the diseased prostate. J Androl 25 (2004) 618
20. Minnery C.H., and Getzenberg R.H. Benign prostatic hyperplasia cell viability and modulation of JM-27 by doxazosin and ibuprofen. J Urol 174 (2005) 375
21. Cannon G.W., Mullins C., Lucia M.S., Hayward S.W., Lin V., Liu B.C., et al. A preliminary study of JM-27: a serum marker that can specifically identify men with symptomatic benign prostatic hyperplasia. J Urol 177 (2007) 610
22. Lundwall A., and Lilja H. Molecular cloning of human prostate specific antigen cDNA. FEBS Lett 214 (1987) 317
23. Stenman U.H., Leinonen J., Alfthan H., Rannikko S., Tuhkanen K., and Alfthan O. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 51 (1991) 222
24. Mikolajczyk S.D., Millar L.S., Wang T.J., Rittenhouse H.G., Wolfert R.L., Marks L.S., et al. "BPSA," a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia. Urology 55 (2000) 41
25. Mikolajczyk S.D., Marks L.S., Partin A.W., and Rittenhouse H.G. Free prostate-specific antigen in serum is becoming more complex. Urology 59 (2002) 797
26. Slawin K.M., Shariat S., and Canto E. BPSA: a novel serum marker for benign prostatic hyperplasia. Rev Urol 7 suppl (2005) S52
27. Levitt J.M., and Slawin K.M. Prostate-specific antigen and prostate-specific antigen derivatives as predictors of benign prostatic hyperplasia progression. Curr Prostate Rep 5 (2007) 21
28. Linton H.J., Marks L.S., Millar L.S., Knott C.L., Rittenhouse H.G., and Mikolajczyk S.D. Benign prostate-specific antigen (BPSA) in serum is increased in benign prostate disease. Clin Chem 49 (2003) 253
29. Canto E.I., Singh H., Shariat S.F., Lamb D.J., Mikolajczyk S.D., Linton H.J., et al. Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer. Urology 63 (2004) 905
30. Shariat S.F., Canto E.I., Kattan M.W., and Slawin K.M. Beyond prostate-specific antigen: new serologic biomarkers for improved diagnosis and management of prostate cancer. Rev Urol 6 (2004) 58
31. Morote J., Encabo G., Lopez M., and deTorres I.M. Prediction of prostate volume based on total and free serum prostate-specific antigen: is it reliable?. Eur Urol 38 (2000) 91
32. Debruyne F., Barkin J., vanErps P., Reis M., Tammela T.L., Roehrborn C., et al. Efficacy and safety of long-term treatment with the dual 5alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol 46 (2004) 488
33. Slawin K.M., Levitt J.M., Lamb D.J., Murthy L., Chuang W., Lu H.K., et al. Prediction of prostate volume using molecular forms of PSA in men with BPH enrolled on the GSK Phase III Dutasteride Trials. J Urol 175 suppl (2006) 439 abstract 1363
34. Barry M.J., Fowler Jr. F.J., O'Leary M.P., Bruskewitz R.C., Holtgrewe H.L., Mebust W.K., et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 148 (1992) 1549
35. Barry M.J., Fowler Jr. F.J., O'Leary M.P., Bruskewitz R.C., Holtgrewe H.L., and Mebust W.K. Measuring disease-specific health status in men with benign prostatic hyperplasia. Measurement Committee of the American Urological Association. Med Care 33 (1995) AS145
36. Slawin K.M., Levitt J.M., Lamb D.J., Murthy L., Chuang W., Lu H.K., et al. Baseline serum BPH-A level enhances the accuracy of a nomogram to predict BPH progression in men enrolled on the GSK Phase III Dutasteride Trials. J Urol 175 suppl (2006) 436 abstract 1352
37. Slawin K.M., Kattan M.W., Roehrborn C.G., and Wilson T. Development of nomogram to predict acute urinary retention or surgical intervention, with or without dutasteride therapy, in men with benign prostatic hyperplasia. Urology 67 (2006) 84
38. Lazzeri E., and Romagnani P. CXCR3-binding chemokines: novel multifunctional therapeutic targets. Curr Drug Targets Immune Endocr Metabol Disord 5 (2005) 109
39. Liu L., Callahan M.K., Huang D., and Ransohoff R.M. Chemokine receptor CXCR3: an unexpected enigma. Curr Top Dev Biol 68 (2005) 149
40. Niehrs C. Function and biological roles of the Dickkopf family of Wnt modulators. Oncogene 25 (2006) 7469
41. Falk J., Bonnon C., Girault J.A., and Faivre-Sarrailh C. F3/contactin, a neuronal cell adhesion molecule implicated in axogenesis and myelination. Biol Cell 94 (2002) 327
42. Hu Q.D., Ang B.T., Karsak M., Hu W.P., Cui X.Y., Duka T., et al. F3/contactin acts as a functional ligand for Notch during oligodendrocyte maturation. Cell 115 (2003) 163
43. Hu Q.D., Ma Q.H., Gennarini G., and Xiao Z.C. Cross-talk between F3/contactin and Notch at axoglial interface: a role in oligodendrocyte development. Dev Neurosci 28 (2006) 25
44. Ibrahim S.N., Lightner V.A., Ventimiglia J.B., Ibrahim G.K., Walther P.J., Bigner D.D., et al. Tenascin expression in prostatic hyperplasia, intraepithelial neoplasia, and carcinoma. Hum Pathol 24 (1993) 982
45. Lynch Jr. D.F., Hassen W., Clements M.A., Schellhammer P.F., and Wright Jr. G.L. Serum levels of endothelial and neural cell adhesion molecules in prostate cancer. Prostate 32 (1997) 214
46. McConnell J.D., Bruskewitz R., Walsh P., Andriole G., Lieber M., Holtgrewe H.L., et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 338 (1998) 557
47. Bruskewitz R. Management of symptomatic BPH in the US: who is treated and how?. Eur Urol 36 suppl (1999) 7
48. Tomlins S.A., Mehra R., Rhodes D.R., Cao X., Wang L., Dhanasekaran S.M., et al. Integrative molecular concept modeling of prostate cancer progression. Nat Genet 39 (2007) 41
49. Tomlins S.A., Mehra R., Rhodes D.R., Shah R.B., Rubin M.A., Bruening E., et al. Whole transcriptome amplification for gene expression profiling and development of molecular archives. Neoplasia 8 (2006) 153
50. Ehrlich J.R., Caiazzo Jr. R.J., Qiu W., Tassinari O.W., O'Leary M.P., Richie J.P., et al. A native antigen reverse capture microarray platform for autoantibody profiling of prostate cancer sera. Proteomics Clin Appl 1 (2007) 476